MX2022005350A - El uso de una formulacion liposomal cationica que comprende paclitaxel y uno o mas lipidos cationicos, y opcionalmente gemcitabina, para el tratamiento de cancer pancreatico refractario o resistente. - Google Patents

El uso de una formulacion liposomal cationica que comprende paclitaxel y uno o mas lipidos cationicos, y opcionalmente gemcitabina, para el tratamiento de cancer pancreatico refractario o resistente.

Info

Publication number
MX2022005350A
MX2022005350A MX2022005350A MX2022005350A MX2022005350A MX 2022005350 A MX2022005350 A MX 2022005350A MX 2022005350 A MX2022005350 A MX 2022005350A MX 2022005350 A MX2022005350 A MX 2022005350A MX 2022005350 A MX2022005350 A MX 2022005350A
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
treatment
effective amount
therapeutically effective
cationic
Prior art date
Application number
MX2022005350A
Other languages
English (en)
Inventor
Ruey - Kuen HSIEH
Hui - Yuan Tseng
Shi - Ting Lin
Original Assignee
Syncore Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syncore Biotechnology Co Ltd filed Critical Syncore Biotechnology Co Ltd
Publication of MX2022005350A publication Critical patent/MX2022005350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método de tratamiento de cáncer pancreático refractario o resistente por administración: (i) una formulación liposomal catiónica que comprende uno o más lípidos catiónicos 5 y una cantidad de paclitaxel terapéuticamente eficaz; o (ii) una formulación liposomal catiónica que comprende uno o más lípidos catiónicos y una cantidad de paclitaxel terapéuticamente eficaz, y cantidad de gemcitabina terapéuticamente eficaz.
MX2022005350A 2017-01-05 2019-07-04 El uso de una formulacion liposomal cationica que comprende paclitaxel y uno o mas lipidos cationicos, y opcionalmente gemcitabina, para el tratamiento de cancer pancreatico refractario o resistente. MX2022005350A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762442636P 2017-01-05 2017-01-05

Publications (1)

Publication Number Publication Date
MX2022005350A true MX2022005350A (es) 2022-06-02

Family

ID=62789060

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008132A MX2019008132A (es) 2017-01-05 2018-01-04 Tratamiento para el cancer pancreatico.
MX2022005350A MX2022005350A (es) 2017-01-05 2019-07-04 El uso de una formulacion liposomal cationica que comprende paclitaxel y uno o mas lipidos cationicos, y opcionalmente gemcitabina, para el tratamiento de cancer pancreatico refractario o resistente.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019008132A MX2019008132A (es) 2017-01-05 2018-01-04 Tratamiento para el cancer pancreatico.

Country Status (11)

Country Link
US (2) US20190380994A1 (es)
EP (1) EP3565530A4 (es)
JP (2) JP2020504138A (es)
KR (1) KR20190103304A (es)
CN (1) CN110267650A (es)
AU (1) AU2018205544B2 (es)
BR (1) BR112019013983A2 (es)
CA (1) CA3049183A1 (es)
IL (1) IL267613B1 (es)
MX (2) MX2019008132A (es)
WO (1) WO2018127082A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN110974954B (zh) * 2019-12-24 2021-03-16 珠海丽凡达生物技术有限公司 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
WO2024160190A1 (zh) * 2023-01-31 2024-08-08 石药集团中奇制药技术（石家庄）有限公司 紫杉醇阳离子脂质体治疗肿瘤的用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW197439B (es) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
JPH08500973A (ja) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション タキソール、関連タキサン及び他の新規な抗癌／抗ウイルス性化合物原料としてのイチイ培養組織
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5821263A (en) 1996-08-26 1998-10-13 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
WO1998022451A1 (fr) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Derives taxol
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
EP2108362B1 (en) 2002-06-26 2013-05-29 MediGene AG A cationic liposomal preparation comprising a taxane
EP2286794B8 (en) * 2003-10-15 2016-06-01 SynCore Biotechnology CO., LTD Use of cationic liposomes comprising paclitaxel
JP5700909B2 (ja) 2005-05-04 2015-04-15 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
EP2010151B8 (en) * 2006-03-22 2017-01-11 SynCore Biotechnology CO., LTD Treatment of triple receptor negative breast cancer
CA2831206A1 (en) * 2010-04-23 2011-10-27 Niiki Pharma Inc. Method for treating pancreatic cancer
TWI760319B (zh) * 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
JP7025412B2 (ja) * 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法

Also Published As

Publication number Publication date
AU2018205544A1 (en) 2019-06-27
MX2019008132A (es) 2019-09-13
TW201825087A (zh) 2018-07-16
BR112019013983A2 (pt) 2020-04-28
EP3565530A1 (en) 2019-11-13
CA3049183A1 (en) 2018-07-12
CN110267650A (zh) 2019-09-20
EP3565530A4 (en) 2020-07-01
KR20190103304A (ko) 2019-09-04
US20230035723A1 (en) 2023-02-02
IL267613A (en) 2019-08-29
JP2020504138A (ja) 2020-02-06
US20190380994A1 (en) 2019-12-19
RU2019124441A (ru) 2021-02-05
WO2018127082A1 (en) 2018-07-12
JP2022180464A (ja) 2022-12-06
RU2019124441A3 (es) 2021-04-21
AU2018205544B2 (en) 2024-02-29
IL267613B1 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011234A (es) Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3).
MX2020009154A (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
MX2022005350A (es) El uso de una formulacion liposomal cationica que comprende paclitaxel y uno o mas lipidos cationicos, y opcionalmente gemcitabina, para el tratamiento de cancer pancreatico refractario o resistente.
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
EP3581182A4 (en) DRUG COMBINATION FOR THE TREATMENT OF PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
PH12017501879A1 (en) Methods for treating cancer
NZ761519A (en) Nlrp3 modulators
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
MX2017009246A (es) Farmaco de combinacion.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
ZA202302155B (en) Interferon-based cancer treatment method and pharmaceutical composition
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
MY200161A (en) Bacteria for targeting tumors and treating cancer
EA202193276A1 (ru) Способы лечения холангиокарциномы
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2020001759A (es) Inhibidores de histona acetiltransferasa de la familia myst.